Some commentary on maximizing the statistician's value to the pharmaceutical industryDONAHUE, Rafe M. J.Drug information journal. 2000, Vol 34, Num 4, pp 1261-1264, issn 0092-8615Article

Hepatitis B and hepatitis C in Pakistan : prevalence and risk factorsASAD ALI, Syed; DONAHUE, Rafe M. J; QURESHI, Huma et al.International journal of infectious diseases. 2009, Vol 13, Num 1, pp 9-19, issn 1201-9712, 11 p.Article

Tibial Artery Calcification as a Marker of Amputation Risk in Patients With Peripheral Arterial Disease. CommentaryGUZMAN, Raul J; BRINKLEY, D. Marshal; SCHUMACHER, Paul M et al.Journal of the American College of Cardiology. 2008, Vol 51, Num 20, pp 1967-1976, issn 0735-1097, 10 p.Article

Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depressionWEIHS, Karen L; HOUSER, Trisha L; BATEY, Sharyn R et al.Biological psychiatry (1969). 2002, Vol 51, Num 9, pp 753-761, issn 0006-3223Article

Do Bupropion SR and sertraline differ in their effects on anxiety in depressed patients?TRIVEDI, Madhukar H; RUSH, A. John; CARMODY, Thomas J et al.The Journal of clinical psychiatry. 2001, Vol 62, Num 10, pp 776-781, issn 0160-6689Article

Does pretreatment anxiety predict response to either bupropion SR or sertraline?RUSH, A. John; BATEY, Sharyn R; DONAHUE, Rafe M. J et al.Journal of affective disorders. 2001, Vol 64, Num 1, pp 81-87, issn 0165-0327Article

Prevalence of sexual dysfunction among newer antidepressantsCLAYTON, Anita H; PRADKO, James F; CROFT, Harry A et al.The Journal of clinical psychiatry. 2002, Vol 63, Num 4, pp 357-366, issn 0160-6689Article

Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertralineRUSH, A. John; TRIVEDI, Madhukar H; CARMODY, Thomas J et al.Neuropsychopharmacology (New York, NY). 2001, Vol 25, Num 1, pp 131-138, issn 0893-133XArticle